Vibalogics invests $50M toward viral vector manufacturing facility

Vibalogics, a global contract development and manufacturing organization (CDMO) that specializes in the production of oncolytic viruses, viral vector vaccines and viral vector gene therapy products, has commenced the first stage of its $50 million dollar investment at its Cuxhaven, Germany cGMP (current good manufacturing practice) facility, which will involve expanding early-to-late phase clinical virotherapy manufacturing capacity.

The project will see the German CDMO purchase the facility outright, as the company currently leases the site.

The expansion will devote over 100,000 square feet toward service process development, drug substance manufacturing, drug product fill and quality control batch release and stability studies. It will allow for more BSL-2 classified areas, with up to 500L single-use-bioreactors for the manufacture of viral-derived products. The site will ensure seamless technical transfer as applicable to Vibalogics’ soon-to-be-operational late-and-commercial phase facility in the Boston area, which is expected to open up later this year.

Vibalogics expects the initial site expansions to be in place and ready for cGMP operations by January 2022, with plans to continue the same year for ongoing growth of the location.